Join the National Pharmaceutical Council (NPC) for a webinar, “Health Care Coverage Challenges: New Treatments With High Upfront Costs, Long-term Benefits, and Delayed Savings,” highlighting its recently published paper examining the disconnect between the short-term budget impact of a treatment and its downstream effects on payers and society.
Register now to join us from 3:30 – 4:30 p.m. EST March 29.
Many new treatments have significant upfront costs while delivering benefits, including reduction in health care utilization and costs, over time. For example, new therapies that cure hepatitis C require a significant upfront investment, but are curative and reduce long-term costs compared with years of living with the disease and its complications. The gaps between those upfront costs and their long-term benefits and savings create challenges for employers, insurers, governments and others financing health care and making decisions about coverage. With hepatitis C treatments, the immediate budget implications of covering the treatments led many insurers, including state Medicaid programs, to limit access.
These challenges multiply when considered in the broader context of the health coverage market, including people changing insurers and health plans over time. Government programs are particularly affected, given the large-scale shift of people into the Medicare program upon reaching age 65 and that Medicaid eligibility may change monthly.